Sugi Predict

Sugi Predict / Compounds / SCHEMBL24322959

SCHEMBL24322959

SCHEMBL24322959

COC(=O)c1c(C)csc1NC(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 9/20 0.49
▸ MAPK9 P45984 9/20 0.49
▸ MAPK10 P53779 9/20 0.49
▸ MAPT P10636 5/20 0.41
▸ CYP3A4 P08684 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ SCN1A P35498 1/20 0.38
▸ SCN2A Q99250 1/20 0.38
▸ SCN3A Q9NY46 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ ACHE P22303 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.37
▸ THRB P10828 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ PRKCZ Q05513 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24322196 0.83 MAPT (0.39) MAPTALDH1A1HPGDTDP1
SCHEMBL24322190 0.81 MELK (0.40) MAPK8MAPK9MAPK10MAPTCYP1A2
SCHEMBL10713709 0.81 MAPK8 (0.52) MAPK8MAPK9MAPK10MAPTCYP3A4
SCHEMBL9852547 0.77 ALDH1A1 (0.50) MAPK8MAPK9MAPK10MAPTCYP3A4
SCHEMBL24322907 0.76 MAPK8 (0.46) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL31392463 0.75 MAPK8 (0.54) MAPK8MAPK9MAPK10MAPTTP53
SCHEMBL13861476 0.74 MAPT (0.61) MAPK8MAPK9MAPK10MAPTCYP3A4
SCHEMBL11579947 0.72 MAPK8 (0.45) MAPK8MAPK9MAPK10MAPTCYP3A4
SCHEMBL3864643 0.72 MEN1 (0.50) MAPTCYP3A4CYP1A2ALDH1A1HPGD
SCHEMBL1041240 0.72 ALDH1A1 (0.59) MAPK8MAPK9MAPK10MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 — — US disclosed
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 — — US disclosed
CN-116583283-A CDK inhibitors and their use as pharmaceuticals 普莱鲁德疗法有限公司 2023-08-11 — — CN disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 — — US disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 — — US disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 MAPK8 228/4885MAPK9 137/4885MAPK10 246/4885
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 MAPK8 228/4885MAPK9 137/4885MAPK10 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.